-
13316-100A compound used to attach biotin to primary amines, such as those found on lysines on the surface of proteins contains six-atom spacer arm.
-
13316-250A compound used to attach biotin to primary amines, such as those found on lysines on the surface of proteins contains six-atom spacer arm.
-
13316-500A compound used to attach biotin to primary amines, such as those found on lysines on the surface of proteins contains six-atom spacer arm.
-
13304-10A biotinylating reagent that contains two aminohexanoic spacers to increase the efficiency of avidin-binding by alleviating steric hindrance.
-
13304-25A biotinylating reagent that contains two aminohexanoic spacers to increase the efficiency of avidin-binding by alleviating steric hindrance.
-
13304-5A biotinylating reagent that contains two aminohexanoic spacers to increase the efficiency of avidin-binding by alleviating steric hindrance.
-
14242-1A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-10A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-25A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
14242-5A DR5 agonist (Kd= 1.2 µM IC<sub>50</sub> = 2 µM) that induces DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells.
-
11054-1A synthetic intermediate for pharmaceutical synthesis.
-
11054-5A synthetic intermediate for pharmaceutical synthesis.